Expanded board to enable iVexSol to advance growth strategy and address lentiviral vector shortage for CGT

LEXINGTON, MA, AUGUST 29, 2023 – iVexSol Inc., a next-generation stable lentiviral vector manufacturing company, today announced the expanded appointment of veteran biopharma executive Ian F. Smith to the company’s Board of Directors.

Ian has previously served on iVexSol’s Strategic Advisory Board, supporting the company’s launch of its proprietary stable lentiviral vector (LVV) manufacturing platform.

iVexSol is now engaging with multiple biopharmaceutical and industry partners to dramatically increase the speed and quality of LVV production. As the company accelerates its growth strategy to solve the LVV shortages that are severely restricting patient access to CAR-T cell therapies and other advanced therapeutics, Ian will bring extensive biotech industry acumen to scaling and advancing iVexSol’s business.

“The expansion of Ian’s role to iVexSol’s Board of Directors will broaden the reach of our technology and help to drive our company growth,” said CEO and Co-founder Dr. Rodney Rietze, Ph.D. “His proven experience with both regenerative medicines and business leadership will provide invaluable guidance as we scale our lentiviral vector technology to support a growing number of cell therapies and the patients they serve.”

“I’m very much looking forward to working with Ian on our Board of Directors,” said Joe Gentile, Chairman of the Board for iVexSol. “His successful experience shepherding an array of therapeutics companies through critical stages of growth has provided him with a seasoned vantage point. We look forward to Ian’s expanded role at the company and collaborating to solve critical roadblocks for cell and gene therapies.”

Ian is a biotechnology leader with more than 20 years of finance and operations experience. He serves as a senior advisor to Bain Capital Life Sciences, a member of the Board of Directors of Foghorn Therapeutics Board, Executive Chair of Solid Biosciences (gene therapy for Duchenne Muscular Dystrophy and other diseases) and served as Executive Chair of Viacyte Inc (cell therapy for diabetes) prior to the company's acquisition by Vertex, and as a board member of AavantiBio (gene therapy for Fredrich's Ataxia) prior to its merger with Solid Biosciences. Prior to this, Ian was Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals Inc., as well as Chief Financial Officer between 2001 and 2019.

To learn more about iVexSol, please visit ivexsol.com.

About iVexSol

iVexSol, Inc. is a next-generation lentiviral vector manufacturing company that transforms the way these essential gene-delivery vehicles are made. Our solution is founded on a proprietary, advanced, stable lentiviral vector production process. iVexSol’s Intelligent Manufacturing^® greatly reduces the complexity, cost, and development time for these critical components, solving lentiviral vector capacity and accelerating greater access to life-changing cell and gene therapies. For more information, please visit www.ivexsol.com.

Media Contact:
Cathryn Brown
cbrown@ivexsol.com